Suzhou Zelgen Biopharmaceuticals Co.,Ltd: all 83 studies

Page 1 of 1. Open to participants first (30), then studies with results posted, then the rest; newest registration first within each.

• ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine CarcinomaNot yet recruitingNCT07833839Phase 3
• ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced HepatocellularNot yet recruitingNCT07813572Phase 3
• A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine CarcinomaNot yet recruitingNCT07595913Phase 3
• Study of ZGGS34 in Participants With Advanced Solid TumorsRecruitingNCT07258121Phase 1/2
• Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung CancerRecruitingNCT07231445Phase 1
• Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung CancerRecruitingNCT07189455Phase 3
• Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid TumorsNot yet recruitingNCT07142837Phase 1/2
• Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract CarcinomaRecruitingNCT07099547Phase 2
• Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical CancerRecruitingNCT07080216Phase 1/2
• ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaRecruitingNCT07038096Phase 1/2
• Study of ZG006 in Participants With Neuroendocrine Prostate CancerNot yet recruitingNCT07024277Phase 2
• Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid TumorsRecruitingNCT06938880Phase 1/2
• Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung CancerRecruitingNCT06903377Phase 1/2
• Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory LymphomaRecruitingNCT06883526Phase 1/2
• A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung CancerRecruitingNCT06592638Phase 1
• Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular CarcinomaRecruitingNCT06558227Phase 2
• Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.RecruitingNCT06440057Phase 1/2
• Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.RecruitingNCT06372626Phase 1/2
• Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung CancerRecruitingNCT06283719Phase 1/2
• Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical CarcinomaRecruitingNCT06241235Phase 1/2
• A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid TumoursRecruitingNCT06237413Phase 1/2
• A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.RecruitingNCT06237400Phase 1/2
• Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaRecruitingNCT05978284Phase 1/2
• Study of ZG0895.HCl in Patients With Advanced Solid TumorsRecruitingNCT05877664Phase 1
• A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus PneumoniaNot yet recruitingNCT05688839Phase 2
• An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus PneumoniaNot yet recruitingNCT05686629Phase 2
• A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic DermatitisRecruitingNCT05676242Phase 3
• Study of ZGGS18 in Patients With Advanced Solid TumorsRecruitingNCT05584800Phase 1/2
• A Safety and Tolerability Study of JaktinibRecruitingNCT05279001Phase 1
• A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.Not yet recruitingNCT04971551Phase 2
• A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants.Active, not recruitingNCT07565597Phase 1
• Study of ZG005 in Patients With Advanced Solid TumorsActive, not recruitingNCT06927687Phase 2
• A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy VolunteersCompletedNCT06246695Phase 1
• A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid TumorStatus unknownNCT06239298Phase 1/2
• A Study of ZG005 in Patients With Advanced Solid TumorsCompletedNCT06233292Phase 1/2
• A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy ParticipantsCompletedNCT06193148Phase 1
• Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting ConditionsCompletedNCT06132243Phase 1
• Study of ZGGS15 in Patients With Advanced Solid TumorsCompletedNCT05864573Phase 1
• Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)CompletedNCT05861128Phase 3
• Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)CompletedNCT05861102Phase 3
• Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)WithdrawnNCT05702788Phase 2
• A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic DermatitisActive, not recruitingNCT05526222Phase 3
• Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia AreataCompletedNCT05255237Phase 3
• ADME Study of [14C]-Jaktinib in Healthy Male SubjectsCompletedNCT05150717Phase 1
• Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia AreataCompletedNCT05051761Phase 3
• Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic FunctionCompletedNCT04993404Phase 1
• Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone WithdrawalCompletedNCT04971473Phase 3
• rhTSH for Radioactive Iodine Remnant Ablation in Participants With Differentiated Thyroid Cancer (DTC)CompletedNCT04964284Phase 3
• Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.TerminatedNCT04866056Phase 1/2
• Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.CompletedNCT04851535Phase 2
• The Mass Balance and Biotransformation of [14C]Donafenib in Healthy Adult ManCompletedNCT04816123Phase 1
• Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk MyelofibrosisCompletedNCT04617028Phase 3
• A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal TumorsTerminatedNCT04612712Phase 1/2
• A Phase 2 Study of Jaktinib in Participants With Moderate to Severe PsoriasisCompletedNCT04612699Phase 2
• Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular CarcinomaActive, not recruitingNCT04605185Phase 1
• Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic DermatitisCompletedNCT04539639Phase 2
• Jaktinib Hydrochloride Tablets In The Treatment of Active Ankylosing SpondylitisCompletedNCT04507659Phase 2
• Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT04503902Phase 1/2
• A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid TumorsStatus unknownNCT04472858Phase 1
• Safety and Efficacy of Topical Recombinant Human Thrombin(rhThrombin) for Surgical HemostasisCompletedNCT04459871Phase 3
• rhTSH for Radioactive Iodine Remnant Ablation in Differentiated Thyroid CancerCompletedNCT04447183Phase 2
• A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia AreataActive, not recruitingNCT04445363Phase 1/2
• Jaktinib Hydrochloride Cream For Atopic DermatitisCompletedNCT04435392Phase 1/2
• Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AMLTerminatedNCT04402723Phase 1
• Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary FibrosisCompletedNCT04312594Phase 2
• Jaktinib for the Treatment of Ruxolitinib Intolerance of MyelofibrosisCompletedNCT04217993Phase 2
• Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With CrizotinibTerminatedNCT04211922Phase 2
• Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized PatientsCompletedNCT04137185Phase 1/2
• Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia AreataCompletedNCT04034134Phase 2
• To Evaluate the Effect of Food on the Pharmacokinetic Characteristics of Alkotinib Capsules in Healthy SubjectsCompletedNCT04032821Phase 1
• Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.CompletedNCT03886415Phase 2
• Topical rhThrombin as an Adjunct to Hemostasis During Segmental HepatectomyCompletedNCT03611426Phase 1/2
• Study of Alkotinib in Patients With Advanced Non Small Cell Lung CancerCompletedNCT03607188Phase 1
• A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid CancerTerminatedNCT03602495Phase 3
• The Tolerance, Pharmacokinetics of Jaktinib in Healthy VolunteersCompletedNCT03314402Phase 1
• Donafenib for Previously Treated Metastatic Colorectal CancerCompletedNCT02870582Phase 3
• Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid CancerCompletedNCT02870569Phase 2
• Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal CarcinomaTerminatedNCT02698111Phase 1/2
• Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular CarcinomaCompletedNCT02645981Phase 2/3
• Donafenib Monotherapy for Previously Treated Metastatic Colorectal CancerCompletedNCT02489916Phase 1/2
• Donafenib Monotherapy for Previously Treated Metastatic Gastric CancerTerminatedNCT02489214Phase 1/2
• A Study of Donafenib Monotherapy in Advanced Oesophageal CancerTerminatedNCT02489201Phase 1/2
• Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular CarcinomaCompletedNCT02229071Phase 1/2

← Suzhou Zelgen Biopharmaceuticals Co.,Ltd overview and focus areas